Last Trading Date: Paris Feb. 6, 2026
- L’Oréal shares slipped 0.16% to €394.05 on Friday, Feb. 6, with little after-hours movement as investors stayed cautious ahead of annual results despite recent analyst upgrades.
- Barclays, UBS, and Goldman Sachs have raised price targets into the €430–€435 range, citing improving beauty market trends, even as consensus targets remain close to current levels.
- Traders are now focused on L’Oréal’s annual earnings release and investor meeting next week, watching for guidance, China demand signals, and margin commentary as key near-term catalysts.
Shares of L’Oréal S.A. (EPA: OREP) edged lower on the last full trading session, closing the week in the red amid rising anticipation for the company’s 2025 annual results and follow-on investor commentary. In a relatively quiet but context-rich session ahead of next week’s key catalysts, the cosmetics giant’s stock closed down 0.16 % at €394.05 on Friday, February 6, 2026, marking a modest pullback from recent near-52-week highs and underperforming broader European indices for the day.(investing)
Trading remained tentative through the session, which saw L’Oréal’s shares fluctuate between about €385.70 and €395.10 before settling down slightly as investors balanced bullish analyst sentiment with caution ahead of results. After the market close, in late trading and extended hours, data from Euronext indicates minimal extended-session movement, with the after-hours price largely flat or slightly softer as news flow remained thin.(euronext)
The muted stock performance came even as key brokers recently lifted price targets and ratings, aiming to frame the narrative around L’Oréal’s medium-term prospects. In late January, Barclays upgraded L’Oréal’s rating to “Overweight” from “Underweight”, raising its target to €435 from a prior €325, citing improving cosmetic market growth trends and stronger momentum in key regions like the U.S. and China that could bolster organic expansion in 2026. Analysts at UBS also reframed the stock’s outlook earlier in January with a Buy rating and a €430 price target, a rare positive adjustment underscoring what the firm described as a “rare combination of favourable factors” supporting L’Oréal’s growth trajectory.(investing)
Much of the recent bullish commentary frames L’Oréal as poised to benefit from resilient demand for premium skincare, fragrances, and cosmetics — particularly franchises showing double-digit growth in the first half of 2025 — even as some legacy markets weigh on comps. Goldman Sachs, for instance, maintained a Buy rating and set a €430 target, highlighting robust performance in the fragrance segment as a growth vector.(investing)
However, consensus metrics are more mixed; broader analyst data indicate a mean price target near €397–€403, just above recent closing levels, signalling tempered but constructive expectations.(chartmill)
European equities finished the session with moderate strength in other sectors, though defensive consumer names like L’Oréal often take a backseat in risk-on environments as traders adjust positions ahead of earnings or macro catalysts. Within the luxury and consumer staples space, stocks have exhibited leadership at times — for example, earlier in January, L’Oréal jumped over 6 % when UBS turned bullish — but Friday’s session suggested profit-taking and rotation into cyclicals.